IMR Press / RCM / Volume 23 / Issue 9 / DOI: 10.31083/j.rcm2309304
Open Access Review
Exercise, Erectile Dysfunction and Co-Morbidities: “The Good, the Bad and the Ugly”
Show Less
1 Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece
*Correspondence: (Michael Doumas)
Academic Editor: Fabian Sanchis-Gomar
Rev. Cardiovasc. Med. 2022, 23(9), 304;
Submitted: 17 June 2022 | Revised: 24 July 2022 | Accepted: 17 August 2022 | Published: 9 September 2022
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Erectile dysfunction (ED), defined as the inability to attain or maintain sufficient penile erection for sexual intercourse, is a growing health problem, which unfortunately remains underreported, underdiagnosed and undertreated. Growing evidence suggests that ED is a promising cardiovascular risk marker, as it is associated with major co-morbidities increasing cardiovascular disease burden, while it is an independent predictor of cardiovascular morbidity and mortality. The role of exercise as a non-pharmacological therapeutic intervention in ED has been widely investigated during the last two decades, both in observational studies and in randomized controlled trials, enrolling different patients’ populations. In the present narrative review, we summarize relevant evidence concerning the effect of exercise on vascular ED and the pathophysiologic background, underscoring the importance of enhanced physical activity as a recommendation in all subjects with vascular ED.

erectile dysfunction
physical activity
cardiovascular disease
1. Erectile Dysfunction: An Increasing Health Burden

Erectile dysfunction (ED) is characterized by the inability to attain or maintain sufficient penile erection for achieving sexual intercourse [1]. Rapid assessment of the severity of ED in clinical practice is allowed with the use of the five-question International Index of Erectile Function (IIEF-5) [2].

Its prevalence is rising worldwide, mainly affecting older men, while it is estimated that 12 million men in the United States (US) aged 40–79 years old suffer from ED [2]. Results from the European Male Ageing Study (EMAS) in a sample of 3369 community-dwelling men aged 40–79 years old demonstrated that one out of three men reported ED, while 6% reported severe orgasmic impairment [3]. In the same study, the prevalence of moderate or severe ED was 6%, 19%, 38% and 64% among age groups 40–49, 50–59, 60–69 and above 70, respectively [3].

Formerly published data suggested an increasing prevalence of ED with age, lower education, and major co-morbidities, such as obesity, diabetes mellitus (DM), hypertension, metabolic syndrome and cardiovascular disease (CVD) [4, 5]. ED has both organic and psychogenic components, while, lifestyle factors, such as smoking, sedentary lifestyle and bicycle riding have also been implicated in increased risk for ED manifestation [6]. Moreover, several medications, such as antidepressants, antihypertensives, antiarrhythmics, diuretics, histamine receptor 2 antagonists, antiandrogens, corticosteroids, 5α reductase inhibitors, ketoconazole, and recreational drugs (alcohol, cannabis, cocaine), may also impair erectile function [6].

A meticulous medical and sexual history, a thorough physical examination with emphasis on the genitourinary tract, and routine hormonal and biochemical tests are required for an accurate diagnosis [7]. Physical examination should also focus on signs of hypogonadism, such as the presence of gynecomastia and the distribution of the body hair, and on the cardiovascular system, through measurements of heart rate and blood pressure and the assessment of heart rhythm and peripheral pulses for signs of arterial hypoperfusion, while the assessment of waist circumference and body mass index are also of great significance [7]. Regarding the etiology of ED, simple guided questions can help differentiate psychogenic from organic causes, as a sudden onset, an intermittent course and a short duration of ED point towards psychogenic factors, while a gradual onset, a progressive course and a longer duration are more indicative of an organic etiology [1].

Overall, normal sex life is considered important for the male population, however, only a minority of them request help from specialized healthcare professionals [8]. On the other hand, ED is not an issue commonly addressed by physicians during medical appointments for various reasons. Lack of expertise and practice, downgrading the issue in favor of other health-related problems and reluctance of clinicians to address the problem because they feel uncomfortable with such a discussion with their patients are some of them [1, 2].

2. Erectile Dysfunction and Main Co-Morbidities

DM, both type 1 and type 2, has been strongly associated with increased risk for ED. A former meta-analysis in a total of 88,577 men demonstrated that more than half of men with DM (52.5%) suffer from ED, while men with DM compared to healthy controls featured increased odds for ED [odds ratio (OR) = 3.62; 95% confidence interval (CI); 2.53 to 5.16] [9]. The interconnection between type 2 DM and ED is so close, so that previous data have suggested that screening for ED can improve the diagnostic accuracy of well-established risk scores for the assessment of underdiagnosed type 2 DM [10]. According to recent data from the German Diabetes Study enrolling patients with recently diagnosed DM, men with severe insulin-resistant DM have the highest prevalence of ED, equal to 52%, while the relative frequency of ED is much lower in patients with severe autoimmune DM, equal to 7% [11]. In the same cohort, the prevalence of ED in men with severe insulin-deficient DM, mild obesity-related DM and mild age-related DM was 31%, 18% and 39%, respectively, highly indicative of the significant impact of both insulin resistance and insulin deficiency on normal erectile function [11].

Hypertension has also been recognized as an important risk factor for ED [12, 13]. A previous meta-analysis of observational studies in a total of 121,641 male subjects documented that hypertension is associated with significantly increased odds for the development of ED (OR = 1.74, 95% CI; 1.52 to 2.00), without important geographical disparities [14]. Other meta-analytic data have also confirmed the significantly increased odds for ED in a background of hypertension (OR = 1.84, 95% CI; 1.58 to 2.14) [15], making clear this association.

Chronic kidney disease (CKD) is another, well-described risk factor for ED. A recent meta-analysis of observational studies in a total of 5986 men showed an overall prevalence of ED of 76% among subjects with a CKD diagnosis, while hemodialysis and transplant patients had a lower prevalence of ED [16]. Other meta-analyses have come to similar conclusions regarding the interconnection between CKD and ED [17]. Interestingly, recent data on the prevalence of ED among end-stage renal disease (ESRD) patients are more detailed, showing a prevalence of 59% among renal transplant recipients, 79% among patients on hemodialysis, 71% among patients on peritoneal dialysis and 82% among patients with ESRD starting dialysis [18].

Data regarding the association between ED and dyslipidemia are rather scarce. The overall prevalence of ED among patients with dyslipidemia has been demonstrated to be approximately 12% [19]. This association can also be hypothesized by the significant improvement of erectile function, as quantified by the IIEF score, with the use of lipid-lowering drugs, mainly statins [20, 21], although their beneficial effect is not generally accepted.

Obstructive sleep apnea (OSA) syndrome is another well-known risk factor for ED. A small meta-analysis demonstrated that patients with OSA syndrome feature an increased risk for ED by 82%, compared to subjects without baseline OSA [risk ratio (RR) = 1.82, 95% CI; 1.12 to 2.97] [22]. Subsequently, a larger meta-analysis confirmed this highly significant, clinical observation [23].

Metabolic syndrome is an additional risk factor for ED; a former meta-analysis documented that, subjects with metabolic syndrome experience an increased risk for ED by 60% compared to controls (RR = 1.60, 95% CI; 1.27 to 2.02) [24], a finding that was further confirmed by a later meta-analysis, which also showed that the plasma glucose component of the metabolic syndrome has the greatest prognostic value for the development of ED [25].

Finally, the presence of obesity increases substantially the risk for the development of ED. Specifically, results from the Massachusetts Male Aging Study and the Health Professionals Followup Study cohort showed that obesity doubles the risk for ED [26, 27, 28]. Similar results were also depicted in the European Male Aging Study, in which a body mass index (BMI) above 30 kg/m2 and a waist circumference above 102 cm correlated with worse sexual activity [29]. Interestingly, weight loss through lifestyle interventions or bariatric surgery exerts a positive effect on erectile function, with improvements on the participants’ IIEF scores [30, 31].

3. Erectile Dysfunction and Cardiovascular Disease

A strong association between ED and cardiovascular disease has been established over the years since they share common pathophysiologic mechanisms [32]. ED is highly prevalent among men with cardiovascular disease [33], while ED is an independent risk factor for the development of cardiovascular disease.

ED usually precedes symptomatic cardiovascular disease [34], therefore its identification by healthcare physicians appears to be of utmost importance. A former meta-analysis of observational studies in a total of 36,744 enrolled subjects documented that ED increases the risk for cardiovascular disease by 48% (RR = 1.48, 95% CI; 1.25 to 1.74), for coronary artery disease by 46% (RR = 1.46, 95% CI; 1.31 to 1.63) and for stroke by 35% (RR = 1.35, 95% CI; 1.19 to 1.54) [35]. A significant increase in the risk for all-cause death by 19% was also shown (RR = 1.19, 95% CI; 1.05 to 1.34) [35]. Later meta-analyses confirmed this hazardous association, also highlighting that shorter duration of ED, concomitant DM and current smoking are significant contributors to cardiovascular disease development [36, 37]. Severe ED appears also to predict a higher risk for cardiovascular disease development, compared to milder disease [36].

Besides its strong correlation with surrogate cardiovascular endpoints, ED also correlates with subclinical cardiovascular disease, emphasizing the significance of meticulous cardiovascular risk assessment of patients presenting with ED [38]. More specifically, it has been previously shown that ED is associated with significantly impaired endothelial function, as quantified by flow-mediated dilation (FMD), while it also correlates with increased carotid intima-media thickness (cIMT) [38]. According to a recently published, observational study, ED also correlates with impaired arterial stiffness, with pulse wave velocity (PWV) values found to be increased across the different stages of ED severity, underscoring the association between ED and subclinical cardiovascular disease [39].

Overall, ED represents a valuable cardiovascular risk marker, although it is usually neglected in clinical practice [40].

4. Pathophysiologic Mechanisms Implicated into Erectile Dysfunction

Normally, erection is the result of smooth muscle cell relaxation in the penis, enabling the inflow of blood in the corposa cavernosum and thereby the compression of the subtunical venules, blocking the venous outflow. Any interruption of this veno-occlusive mechanism can lead to the development of ED [6].

Endothelial dysfunction appears to play a catalytic role in the development of ED, with endothelium-derived nitric oxide (NO), synthesized by L-arginine [41], being decisive in regulating smooth muscle tone, and thus, being crucial for penile erection, through relaxation of cavernosal smooth muscles and subsequent compression of the subtunical small veins [1]. Impaired NO synthesis or availability has been demonstrated as a significant factor contributing to endothelial dysfunction, and thus, to ED, while, several diseases and drug classes have been shown to affect the expression of endothelial NO synthase (eNOS), and thus, regulating NO levels [41].

Enhanced oxidative stress and hyperglycemia-induced advanced glycation end (AGE) products seem also to be crucial for the development of ED in patients with DM [42]. Both conditions lead to eNOS inhibition, macromolecular damage, endothelial cell apoptosis and vascular endothelial signaling inhibition, therefore resulting in cavernosal endothelial dysfunction, impairment of vasorelaxation of smooth muscle cells, and finally in manifestation of ED [42].

There is also evidence suggesting a prominent role of testosterone in the pathogenesis of ED. Previous animal studies have shown that androgen deprivation results in structural alterations in the corpus cavernosum and finally, in reduced intracavernosal pressure [43]. Testosterone has been shown to upregulate eNOS, while it downregulates the activity of RhoA-ROCK (Ras homolog gene family member A-Rho-associated, coiled coil containing protein kinase) pathway, which controls the sensitization of penile smooth muscle cells to calcium, and as a result, regulates penile relaxation [44].

Subclinical inflammation and atherosclerosis seem to be crucial for the development of ED, as well. Carotid and coronary artery atherosclerosis has been shown to be highly predictive of ED in human studies [45, 46]. In addition, a significant association between the presence of cavernosal atherosclerotic plaques and ED has been documented [47]. Increasing evidence also suggests the association between ED and inflammation, since increased levels of pro-inflammatory cytokines have been found in ED, along with decreased levels of anti-inflammatory cytokines [48, 49].

Overall, it seems that there is a vicious circle between endothelial dysfunction, oxidative stress, atherosclerosis and inflammation leading to ED (Fig. 1), with NO representing the key mediator. However, a more comprehensive review of the main pathophysiologic mechanisms underlying ED is outside the scope of this manuscript and is discussed in detail elsewhere (for example, [1, 41, 42]).

Fig. 1.

Main pathophysiologic mechanisms implicated in the development of erectile dysfunction.

5. Physical Activity and Erectile Dysfunction: Evidence from Observational Studies

A previous sub-analysis of the Look AHEAD trial (Action for Health in Diabetes), with a total of 373 men with type 2 DM demonstrated that 74.6% of them suffered from ED of different severity (29.1% from mild, 20.7% from moderate and 24.8% from severe ED), with 39.9% of them seeking for medical consultation, while 32.3% of them already used drugs with proven efficacy against ED [50]. Remarkably, cardiorespiratory fitness was significantly protective against ED [odds ratio (OR) = 0.61, 95% CI; 0.47 to 0.78, for each unit of fitness z-score], as shown in the multivariate analysis [50].

In another study from the field of cardiac rehabilitation, enrolling 138 men with confirmed ischemic heart disease and ED, it was shown that a 6-month exercise training program, including interval endurance training on a cycle ergometer, indoor or outdoor general fitness exercises and resistance training, resulted in a significant improvement in achieved erection quality (p < 0.05) [51]. A strong association between erection quality and exercise capacity was also shown [51]. A post-hoc analysis of this study revealed the significant correlation between the change in heart rate recovery and the change in erection quality among subjects following the intensive cardiac rehabilitation program, a finding highly suggestive of the role of autonomic dysfunction in ED [52].

Additional insights were provided by another observational study, enrolling 57 subjects with metabolic syndrome and 48 physically active controls [53]. Regular physical exercise at a level of >400 kcal/day was documented to be highly protective against ED (OR = 0.12, 95% CI; 0.017 to 0.778), while increased fibrinogen levels were shown to be predictive of the presence of ED [53]. In addition, large arterial elasticity was shown to be significantly lower among patients with metabolic syndrome compared to controls, and among patients with ED compared to those with normal erectile function [53]. Collectively, that study suggested once again the role of low-grade inflammation in ED, the vascular dysfunction observed in patients with ED and the protective role of physical activity against the occurrence of ED.

In a large, cross-sectional study from Finland, enrolling 1000 apparently healthy men, free from cardiovascular disease at baseline, it was shown that high-intensity physical activity is protective against ED, decreasing the corresponding odds by almost 50% (OR = 0.50, 95% CI; 0.29 to 0.86) [54]. However, lower intensity of exercise was not shown to ameliorate the risk for ED, highlighting once again the need for regular physical activity to maintain a normal erectile function [54].

6. Physical Activity and Erectile Dysfunction: Evidence from Randomized Controlled Trials

There has been a long and vivid discussion regarding the role of physical activity in ED prevention, primary or secondary.

A former randomized controlled trial (RCT) in a total of 110 obese men aged between 35 and 55 years old without baseline DM, hypertension, or dyslipidemia, demonstrated that a 2-year lifestyle intervention resulted in a significant improvement in erectile function [30]. Specifically, in the intervention arm, an increase in duration of physical activity, mainly aerobic exercise, from 48 to 195 minutes per week, led to a significant increase in IIEF score from 13.9 to 17 (p < 0.001), corresponding to a between-group difference of 3 (p = 0.008) with the control group [30]. Of note, physical activity was shown to be an independent predictor of IIEF score (p = 0.02) [30], highlighting its role in ED.

In another RCT enrolling a total of 60 patients with ED, with a mean age of 50 years and a mean BMI of 27 kg/m2, it was shown that recommendation of physical activity as an additional therapeutic intervention to phosphodiesterase type 5 inhibitor (PDE5i) treatment, compared to PDE5i treatment alone, resulted after 3 months in significant improvement in erectile function (p = 0.003), sexual desire (p = 0.028), intercourse satisfaction (p = 0.001) and IIEF score (p = 0.007) [55]. It is remarkable that physical activity greater than 180 minutes per week was the only independent predictor of normal erection (p = 0.01) and normal IIEF score (p = 0.023) [55]. In another trial enrolling a total of 50 subjects with ED, with a mean age of 57 years, without cardiovascular disease or DM at baseline, it was demonstrated that 150 minutes of moderate intensity aerobic activity per week resulted in a significant improvement in IIEF score after 3 months, compared to the control group (p < 0.05) [56]. Of interest, penile Doppler ultrasonographic assessment revealed a significant improvement in penile vascular markers, such as peak systolic velocity, acceleration time, end-diastolic velocity, resistance index and intimal cavernous thickness, in the physical activity group compared to the control group (p < 0.05 for all comparisons) [56]. Serum concentrations of endothelial progenitor cells and endothelial microparticles, indicative of endothelial apoptosis, were significantly lower in the physical activity group compared to the control group, as well [56].

Another RCT enrolling 75 obese, Asian men, with a mean age of 43.6 years, demonstrated that moderate intensity high-volume aerobic exercise of 200–300 minutes per week, compared to low-volume aerobic exercise of less than 150 minutes per week, resulted after a follow-up period of 24 weeks in a significant increase in IIEF score (p < 0.05), associated with a significant increase in plasma testosterone levels, highlighting the role of androgen deficiency in ED [57]. In another small trial recruiting 20 male patients with ED and metabolic syndrome, with a mean age of 68.5 years, it was once again shown that the combination of tadalafil treatment with a structured exercise training program (3 exercise sessions per week, each session was performed for 30 minutes on a bicycle ergometer or a treadmill) compared to tadalafil treatment alone resulted in a significant increase in IIEF score achieved after 2 months of the applied therapeutic intervention (p < 0.001), while a significant positive association between exercise capacity and erectile function in the whole study cohort was also documented [58].

A formerly published RCT enrolling 85 patients with a recent acute myocardial infarction and ED, who were randomized either to a home-based walking program followed by an outdoor progressive walking program or standard of care, showed that after one month, the exercise group experienced a significant improvement in erectile function (p < 0.0001), while, a significant negative correlation between the presence of ED and the 6-minute walk test (6-MWT) at 30 days after hospital discharge was also documented (p < 0.01) [59]. Another trial recruiting 83 patients with ED in the presence of type 2 DM showed that 3-month intensive glycemic control along with advice for physical exercise was inferior to intensive glycemic control and treatment with sildenafil concerning erectile function, as assessed with IIEF score, since patients allocated to sildenafil treatment experienced a greater improvement compared to those allocated to exercise group (p = 0.012) [60]. Of note, in the entire cohort, patients with a duration of DM less than 5 years experienced a greater improvement in erectile function, compared to those having DM more than 10 years [60].

In a pilot trial enrolling 50 patients with ED and testosterone deficiency, it was shown that a combination of a supervised 20-week physical activity program (3 times per week, 80 minutes in total in each session, consisting of 20 minutes of aerobic exercise, followed by 10 minutes of whole-body stretching and 30 minutes of strength exercise with the last 20 minutes consisting of aerobic exercise once again) with testosterone replacement therapy, compared to testosterone replacement therapy alone, led to a more pronounced improvement in IIEF score (p = 0.028), along with a greater increase in serum testosterone levels (p < 0.001) [61]. What is more, these improvements were maintained after the discontinuation of testosterone replacement in the exercise group, emphasizing its prominent role in ED [61].

A former RCT in a total of 154 patients with ischemic heart disease or implantable cardioverter defibrillator and ED showed that a 12-week combined intervention, including physical exercise training (3 weekly sessions, each one lasting 60 minutes, either supervised or home-based, including bicycling, strength training and stretching exercises), pelvic floor exercise and psychoeducation, compared to usual care, resulted in a significant increase in IIEF score (p < 0.0003), which persisted at 6 months post intervention [62]. Orgasmic function, sexual desire and intercourse satisfaction were also significantly improved in the physical exercise treatment arm [62].

Another RCT enrolling 50 men with localized prostate adenocarcinoma, stage I-II, and ED, demonstrated that a 6-month intervention with an aerobic exercise program (5 supervised walking sessions per week, 30–45 minutes per session, at 55–100% of VO2 peak), compared to usual care, led to a significant increase in IIEF score (p = 0.002), along with a significant improvement in orgasmic satisfaction, sexual desire and intercourse satisfaction; however, no significant between-group difference across prespecified outcomes was shown [63]. Of note, exercise resulted in a significant improvement in endothelial function, as assessed with FMD [63].

Implementation of an interval exercise training program, with the use of a bicycle ergometer at a low intensity of between 60% and 79% of maximum heart rate reserve, in subjects with hypertension and ED for 8 weeks, has been previously shown to improve their erectile function compared to standard of care (p < 0.05) [64]. A significant negative correlation between ED and C-reactive protein (CRP) was also shown, further highlighting the role of subclinical low-grade inflammation in the pathogenesis of ED [64].

A small, recently published RCT enrolling 37 patients undergoing hemodialysis (26 men in total) documented that those patients allocated to the intervention group, consisting of passive pedaling with the use of automatic mini bikes in each hemodialysis session for 20 minutes at a steady rate during the first 2 hours of dialysis, did not result after 12 weeks of intervention in a significant improvement in sexual function [65]. Therefore, passive forms of exercise might not be indicated for ED.

Overall, evidence retrieved from the limited, relevant RCTs suggests that physical exercise, especially aerobic, is associated with a significant improvement in erectile function among men with ED with or without cardiovascular risk factors or established cardiovascular disease. The nature of the intervention in the before mentioned RCTs is also something to consider. Patients were not only advised to exercise regularly and adopt healthier diet schedules, but most importantly, they were followed closely either through monthly visits, telephone calls, small group sessions or supervised exercise programs throughout the intervention period.

7. Physical Activity and Erectile Dysfunction: Evidence from Systematic Reviews and Meta-Analysis

Due to the diversity of the patients included in the RCTs and the interventions regarding physical activity, not many meta-analyses have been done so far regarding this matter. A meta-analysis that included seven eligible studies showed that physical exercise exerts a statistically significant improvement in erectile function. Specifically, a 3.85-point difference was observed in erectile function scores after the implementation of physical activity (95% CI; 2.33 to 5.37), with both short-term and long-term interventions being effective. In subgroup analysis erectile function scores were significantly improved in patients with cardiovascular risk factors alone (4.20; 95% CI; 2.16 to 6.23) and those with either coronary heart disease or radical prostatectomy (2.11; 95% CI; 0.76 to 3.45). However, the predisposing factors for erectile dysfunction, the type and duration of activity and the use of pharmacological treatment differed among the included studies [66].

Moreover, Gerbild et al. [67] conducted a systematic review that sought to determine the levels and type of physical activity needed to improve erectile dysfunction. The study was focused on patients with physical inactivity, obesity, hypertension, metabolic syndrome and cardiovascular disease. The authors stated that a meta-analysis could not be performed, as there was significant heterogeneity in the methods used among the included studies. Specifically, the included population, the assessment of erectile dysfunction and the type, duration, intensity and frequency of physical exercise differed to a great extent among the included studies. Nevertheless, the beneficial effects of physical activity on erectile dysfunction were evident, and the authors concluded that supervised aerobic physical activity of moderate to vigorous intensity performed at least four times per week and for at least 40 minutes can be a valuable and effective tool in the management of erectile dysfunction [67].

8. Physical Activity, Cardiovascular and All-Cause Mortality

Cardiorespiratory fitness has been shown to be a potential predictor of cardiovascular and all-cause mortality, both in the general population and in patients with a previous history of cardiovascular disease.

A former meta-analysis in a total of 102,980 healthy participants confirmed that per 1-metabolic equivalent (MET) higher level of maximal aerobic capacity (MAC) the corresponding risk for all-cause mortality was reduced by 13% (RR = 0.87, 95% CI; 0.84 to 0.90) and the risk for cardiovascular disease was reduced by 15% (RR = 0.85, 95% CI; 0.82 to 0.88) [68]. Patients with low cardiorespiratory fitness had a significantly increased risk for all-cause mortality by 70% and for a major adverse cardiovascular event by 56%, emphasizing the value of physical activity in the field of primary prevention of cardiovascular disease [68].

Among subjects with prior cardiovascular disease, it has also been confirmed by a recent meta-analysis in a total of 159,352 patients that the risk for all-cause mortality was reduced by 19% for each increase in MAC by 1 MET [hazard ratio (HR) = 0.81, 95% CI; 0.74 to 0.88]; however, no statistically significant association between cardiorespiratory fitness and cardiovascular mortality was shown (HR = 0.75, 95% CI; 0.48 to 1.18) [69]. Of note, an increase in MAC by 1 MET among patients with a history of coronary artery disease was shown to decrease the risk for all-cause mortality by 17% (HR = 0.83, 95% CI; 0.76 to 0.91); however, this benefit was not statistically confirmed for patients with a history of heart failure (HR = 0.69, 95% CI; 0.36 to 1.32) [69].

Overall, any level of physical activity has been shown to decrease the risk for all-cause death, as opposed to a sedentary lifestyle [70]. Interestingly, in terms of secondary prevention, exercise-based interventions seem to be similarly efficacious to drug-based interventions for patients with coronary artery disease, stroke or heart failure [71], underscoring the significance of physical exercise and its incorporation in cardiac rehabilitation programs [72].

Based upon the significantly increased prevalence of ED among these populations, as discussed in a previous section, it seems that, besides improvement in ED, the implementation of physical exercise programs can result in a significant decrease in cardiovascular and all-cause mortality.

9. Physical Activity and Pathophysiologic Mechanisms Implicated into Erectile Dysfunction

Exercise has been associated with a significant improvement in markers of inflammation, such as CRP, fibrinogen and pro-inflammatory cytokines, especially in patients with established atherosclerotic cardiovascular disease [73, 74]. However, it is not clear whether high-intensity activity produces a greater reduction in inflammatory burden, as demonstrated in a former meta-analysis [75].

In addition, exercise has been associated with a significant reduction in pro-oxidant products and an increase in antioxidant capacity, confirming the rationale for the antioxidant effects of exercise [76]. In specific patient populations, such as those with concomitant heart failure, exercise may have incremental antioxidant efficacy [77].

All exercise modalities (aerobic, resistance, combined) have been documented to exert a beneficial effect on endothelial function [78]. Regarding resistance training, it has been shown that it produces a significant improvement in endothelial function, regardless of a history of cardiovascular or chronic metabolic disease [79]. Low- to moderate-intensity resistance training program seems to be more efficacious in improving endothelial function, compared to high-intensity [80]. Improvement in endothelial function may be more pronounced in patients with type 2 DM compared to non-diabetic subjects [81].

Exercise also improves macrovascular dysfunction indices, such as arterial stiffness [82]. Of note, aerobic exercise provides a greater reduction in pulse wave velocity, the “gold-standard” of arterial stiffness, compared to other forms of exercise [83, 84]. However, all exercise training interventions have a beneficial effect on arterial stiffness indices [85].

Thus, it appears that exercise ameliorates the major pathophysiologic mechanisms implicated in the pathogenesis of ED.

10. Phosphodiesterase-5 Inhibitors and Exercise Capacity

PDE-5 inhibitors are recommended as the first-line treatment option in ED, with sildenafil being the first member of the class, followed by tadalafil, vardenafil, and avanafil [86, 87]. Combination with other drug classes or treatment approaches, such as antioxidants, low-intensity shockwave therapy, vacuum erectile device, folic acid, metformin hydrochloride, or angiotensin-converting enzyme inhibitors, may be considered in refractory or complicated cases [87].

Sildenafil treatment failed to produce a significant benefit on exercise capacity among patients with heart failure with preserved ejection fraction after 24 weeks of treatment, as demonstrated in the RELAX trial published in 2013 [88]. On the other hand, PDE-5 inhibitors have been shown to improve exercise capacity in patients with heart failure with reduced ejection fraction, as documented by relevant RCTs [89, 90]. These results have been also confirmed by relevant meta-analyses in the field [91, 92].

Other patient populations, such as those suffering from chronic obstructive pulmonary disease, did not also have any remarkable benefit concerning exercise capacity with PDE-5 inhibitor treatment [93]. No benefit on exercise capacity has been shown with PDE-5 inhibition in other chronic respiratory failure disorders, such as idiopathic pulmonary fibrosis [94].

Therefore, at present, it does not seem reasonable to support the hypothesis that treatment with PDE-5 inhibitors can improve exercise capacity in patients with ED, and thus can lead to additional improvement in erectile function.

11. Practical Recommendations Regarding Physical Activity in Patients with Erectile Dysfunction

Apart from the positive psychological effects, physical activity is a valuable tool for overall health improvement. For that reason, the World Health Organization has proposed in detail the amount and type of physical exercise necessary for every age group. Specifically, adults aged 18 to 65 years old should exercise at least 150 to 300 minutes per week, preferably with moderate intensity aerobic exercise. Muscle-strengthening activities should also be performed on two or more days per week [95]. Similarly, a recent meta-analysis showed that 40 minutes for four times per week and for six months of aerobic exercise of moderate intensity combined with resistance training improves significantly the erectile function of males with arterial ED and relevant comorbidities [67]. However, up to date no specific guidelines exist that can guide clinicians and patients in detail about the duration, the intensity and the type of exercise.

It appears that a mixture of different kinds of activities is more beneficial for patients. Aerobic activity, resistance training, combat sports and group activities help patients in various ways, suggesting that a plan combining these training modalities should be encouraged in patients with ED [96]. In a recent review Allen concluded that a combination of a high intensity whole body resistance training two times per week with a moderate intensity aerobic exercise for two days per week and a group activity one day per week with a minimum duration of 45 minutes per session and for more than 16 weeks can be a practical suggestion for such patients. Also, as low adherence to such suggestions is a very common problem in every day clinical practice, of utmost importance is the adoption of strategies to maximize adherence, such as supervised training programs, the adoption of training diaries, the provision of simple instructions and the continuous education of the patients about the benefits of exercise not only on ED, but also in health overall [96].

12. Conclusions

ED represents a growing health problem, significantly affecting patients’ quality of life, although it remains underreported, and thus underdiagnosed and undertreated. It has been established over the last 2 decades as a marker of cardiovascular disease, even at the subclinical level, while it seems to be highly prevalent among subjects with other cardiovascular risk factors.

Exercise represents an intervention that can provide substantial improvement in erectile function of the affected subjects, since it improves most of the implicated pathophysiologic mechanisms. It is therefore of utmost importance to recommend various forms of physical activity, according to the subject’s preferences and after meticulous assessment of co-morbidities, exercise capacity and other demographic factors of specific interest, in patients with ED. Such an approach can result not only in improvement in ED parameters, but also in the overall cardiovascular risk of the patient.

Author Contributions

DP and MD designed the article. AK and KI performed the research. DP wrote the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

Ethics Approval and Consent to Participate

Not applicable.


Not applicable.


This research received no external funding.

Conflict of Interest

The authors declare no conflict of interest.

Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Shamloul R, Ghanem H. Erectile dysfunction. The Lancet. 2013; 381: 153–165.
Rew KT, Heidelbaugh JJ. Erectile Dysfunction. American Family Physician. 2016; 94: 820–827.
Corona G, Lee DM, Forti G, O’Connor DB, Maggi M, O’Neill TW, et al. Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). The Journal of Sexual Medicine. 2010; 7: 1362–1380.
Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, Mckinlay JB. Incidence of Erectile Dysfunction in Men 40 to 69 Years Old: Longitudinal Results from the Massachusetts Male Aging Study. Journal of Urology. 2000; 163: 460–463.
Kaya E, Sikka SC, Gur S. A Comprehensive Review of Metabolic Syndrome Affecting Erectile Dysfunction. The Journal of Sexual Medicine. 2015; 12: 856–875.
Muneer A, Kalsi J, Nazareth I, Arya M. Erectile dysfunction. British Medical Journal. 2014; 348: g129.
Yafi FA, Jenkins L, Albersen M, Corona G, Isidori AM, Goldfarb S, et al. Erectile dysfunction. Nature Reviews Disease Primers. 2016; 2: 16003.
Geerkens MJM, Al-Itejawi HHM, Nieuwenhuijzen JA, Meuleman EJM, Lissenberg-Witte BI, van Moorselaar RJA, et al. Sexual Dysfunction and Bother Due to Erectile Dysfunction in the Healthy Elderly Male Population: Prevalence from a Systematic Review. European Urology Focus. 2020; 6: 776–790.
Kouidrat Y, Pizzol D, Cosco T, Thompson T, Carnaghi M, Bertoldo A, et al, Veronese N. High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabetic Medicine. 2017; 34: 1185–1192.
Carrillo-Larco RM, Luza-Dueñas AC, Urdániga-Hung M, Bernabé-Ortiz A. Diagnosis of erectile dysfunction can be used to improve screening for Type 2 diabetes mellitus. Diabetic Medicine. 2018; 35: 1538–1543.
Maalmi H, Herder C, Bönhof GJ, Strassburger K, Zaharia O, Rathmann W, et al. Differences in the prevalence of erectile dysfunction between novel subgroups of recent-onset diabetes. Diabetologia. 2022; 65: 552–562.
Manolis A, Doumas M. Sexual dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications. Journal of Hypertension. 2008; 26: 2074–2084.
Doumas M, Douma S. Sexual Dysfunction in Essential Hypertension: Myth or Reality? The Journal of Clinical Hypertension. 2006; 8: 269–274.
Ning L, Yang L. Hypertension might be a risk factor for erectile dysfunction: a meta-analysis. Andrologia. 2017; 49: e12644.
Wang X, Huang W, Zhang Y. Relation between hypertension and erectile dysfunction: a meta-analysis of cross-section studies. International Journal of Impotence Research. 2018; 30: 141–146.
Pizzol D, Xiao T, Yang L, Demurtas J, McDermott D, Garolla A, et al. Prevalence of erectile dysfunction in patients with chronic kidney disease: a systematic review and meta-analysis. International Journal of Impotence Research. 2021; 33: 508–515.
Navaneethan SD, Vecchio M, Johnson DW, Saglimbene V, Graziano G, Pellegrini F, et al. Prevalence and Correlates of Self-Reported Sexual Dysfunction in CKD: a Meta-analysis of Observational Studies. American Journal of Kidney Diseases. 2010; 56: 670–685.
Pyrgidis N, Mykoniatis I, Nigdelis MP, Kalyvianakis D, Memmos E, Sountoulides P, et al. Prevalence of Erectile Dysfunction in Patients With End-Stage Renal Disease: A Systematic Review and Meta-Analysis. The Journal of Sexual Medicine. 2021; 18: 113–120.
Lee JC, Bénard F, Carrier S, Talwar V, Defoy I. Do men with mild erectile dysfunction have the same risk factors as the general erectile dysfunction clinical trial population? BJU International. 2011; 107: 956–960.
Cai X, Tian Y, Wu T, Cao CX, Bu SY, Wang KJ. The role of statins in erectile dysfunction: a systematic review and meta-analysis. Asian Journal of Andrology. 2014; 16: 461–466.
Kostis JB, Dobrzynski JM. The effect of statins on erectile dysfunction: a meta-analysis of randomized trials. The Journal of Sexual Medicine. 2014; 11: 1626–1635.
Liu L, Kang R, Zhao S, Zhang T, Zhu W, Li E, et al. Sexual Dysfunction in Patients with Obstructive Sleep Apnea: a Systematic Review and Meta-Analysis. The Journal of Sexual Medicine. 2015; 12: 1992–2003.
Kellesarian SV, Malignaggi VR, Feng C, Javed F. Association between obstructive sleep apnea and erectile dysfunction: a systematic review and meta-analysis. International Journal of Impotence Research. 2018; 30: 129–140.
Liu LH, Zhang T, Zhang YR, Liu TS, Zhang HB, Chen FZ, et al. Metabolic syndrome and risk for ED: a meta-analysis. International Journal of Impotence Research. 2014; 26: 196–200.
Besiroglu H, Otunctemur A, Ozbek E. The Relationship between Metabolic Syndrome, its Components, and Erectile Dysfunction: a Systematic Review and a Meta-Analysis of Observational Studies. The Journal of Sexual Medicine. 2015; 12: 1309–1318.
Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. A Prospective Study of Risk Factors for Erectile Dysfunction. Journal of Urology. 2006; 176: 217–221.
Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000; 56: 302–306.
Maggi M, Corona G, Rastrelli G, Filippi S, Vignozzi L, Mannucci E. Erectile dysfunction and central obesity: an Italian perspective. Asian Journal of Andrology. 2014; 16: 581–591.
Han TS, Tajar A, O’Neill TW, Jiang M, Bartfai G, Boonen S, et al. Impaired quality of life and sexual function in overweight and obese men: the European Male Ageing Study. European Journal of Endocrinology. 2011; 164: 1003–1011.
Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D’Andrea F, et al. Effect of Lifestyle Changes on Erectile Dysfunction in Obese Men: a randomized controlled trial. Journal of the American Medical Association. 2004; 291: 2978–2984
Reis LO, Favaro WJ, Barreiro GC, de Oliveira LC, Chaim EA, Fregonesi A, et al. Erectile dysfunction and hormonal imbalance in morbidly obese male is reversed after gastric bypass surgery: a prospective randomized controlled trial. International Journal of Andrology. 2010; 33: 736–744.
Imprialos KP, Stavropoulos K, Doumas M, Tziomalos K, Karagiannis A, Athyros VG. Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. Current Vascular Pharmacology. 2018; 16: 130–142.
Hatzichristou D, Tsimtsiou Z. Prevention and Management of Cardiovascular Disease and Erectile Dysfunction: toward a Common Patient-Centered, Care Model. The American Journal of Cardiology. 2005; 96: 80M–84M.
Mostafaei H, Mori K, Hajebrahimi S, Abufaraj M, Karakiewicz PI, Shariat SF. Association of erectile dysfunction and cardiovascular disease: an umbrella review of systematic reviews and meta-analyses. BJU International. 2021; 128: 3–11.
Dong J, Zhang Y, Qin L. Erectile Dysfunction and Risk of Cardiovascular Disease: meta-analysis of prospective cohort studies. Journal of the American College of Cardiology. 2011; 58: 1378–1385.
Zhao B, Hong Z, Wei Y, Yu D, Xu J, Zhang W. Erectile Dysfunction Predicts Cardiovascular Events as an Independent Risk Factor: A Systematic Review and Meta-Analysis. The Journal of Sexual Medicine. 2019; 16: 1005–1017.
Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI. Prediction of Cardiovascular Events and all-Cause Mortality with Erectile Dysfunction: a systematic review and meta-analysis of cohort studies. Circulation: Cardiovascular Quality and Outcomes. 2013; 6: 99–109.
Osondu CU, Vo B, Oni ET, Blaha MJ, Veledar E, Feldman T, et al. The relationship of erectile dysfunction and subclinical cardiovascular disease: A systematic review and meta-analysis. Vascular Medicine. 2018; 23: 9–20.
Demirelli E, Karagöz A, Öğreden E, Oğuz U, Vural A, Aksu M, et al. The relationship between the severity of erectile dysfunction and aortic stiffness. Andrologia. 2020; 52: e13544
Nehra A, Jackson G, Miner M, Billups KL, Burnett AL, Buvat J, et al. Diagnosis and Treatment of Erectile Dysfunction for Reduction of Cardiovascular Risk. Journal of Urology. 2013; 189: 2031–2038.
Maas R, Schwedhelm E, Albsmeier J, Böger RH. The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vascular Medicine. 2002; 7: 213–225.
Castela Â, Costa C. Molecular mechanisms associated with diabetic endothelial–erectile dysfunction. Nature Reviews Urology. 2016; 13: 266–274.
Saad F, Grahl AS, Aversa A, Yassin AA, Kadioglu A, Moncada I, et al. Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction. BJU International. 2007; 99: 988–992.
Rastrelli G, Corona G, Maggi M. Testosterone and sexual function in men. Maturitas. 2018; 112: 46–52.
Deger M, Ozmen C, Akdogan N, Tepe O, Yucel SP, Izol V. The Relationship between Gensini Score and Erectile Dysfunction in Patients with Chronic Coronary Syndrome. Sexual Medicine. 2021; 9: 100376.
Feldman DI, Cainzos-Achirica M, Billups KL, DeFilippis AP, Chitaley K, Greenland P, et al. Subclinical Vascular Disease and Subsequent Erectile Dysfunction: The Multiethnic Study of Atherosclerosis (MESA). Clinical Cardiology. 2016; 39: 291–298.
Caretta N, Feltrin G, Tarantini G, D’Agostino C, Tona F, Schipilliti M, et al. Erectile Dysfunction, Penile Atherosclerosis, and Coronary Artery Vasculopathy in Heart Transplant Recipients. The Journal of Sexual Medicine. 2013; 10: 2295–2302.
Araña Rosaínz MDJ, Ojeda MO, Acosta JR, Elías‐Calles LC, González NO, Herrera OT, et al. Imbalanced Low-Grade Inflammation and Endothelial Activation in Patients with Type 2 Diabetes Mellitus and Erectile Dysfunction. The Journal of Sexual Medicine. 2011; 8: 2017–2030.
Mishra M, Kumar H, Bajpai S, Singh RK, Tripathi K. Level of serum IL-12 and its correlation with endothelial dysfunction, insulin resistance, proinflammatory cytokines and lipid profile in newly diagnosed type 2 diabetes. Diabetes Research and Clinical Practice. 2011; 94: 255–261.
Rosen RC, Wing RR, Schneider S, Wadden TA, Foster GD, West DS, et al. Erectile dysfunction in type 2 diabetic men: relationship to exercise fitness and cardiovascular risk factors in the Look AHEAD trial. The Journal of Sexual Medicine. 2009; 6: 1414–1422.
Kałka D, Domagała Z, Dworak J, Womperski K, Rusiecki L, Marciniak W, et al. Association between physical exercise and quality of erection in men with ischaemic heart disease and erectile dysfunction subjected to physical training. Kardiologia Polska. 2013; 71: 573–580.
Kałka D, Domagała Z, Rusiecki L, Karpiński Ł, Gebala J, Kolęda P, et al. Heart rate recovery, cardiac rehabilitation and erectile dysfunction in males with ischaemic heart disease. The Anatolian Journal of Cardiology. 2016; 16: 256–263.
Pohjantähti-Maaroos H, Palomäki A, Hartikainen J. Erectile dysfunction, physical activity and metabolic syndrome: differences in markers of atherosclerosis. BMC Cardiovascular Disorders. 2011; 11: 36.
Ettala OO, Syvänen KT, Korhonen PE, Kaipia AJ, Vahlberg TJ, Boström PJ, et al. High-intensity physical activity, stable relationship, and high education level associate with decreasing risk of erectile dysfunction in 1,000 apparently healthy cardiovascular risk subjects. The Journal of Sexual Medicine. 2014; 11: 2277–2284.
Maio G, Saraeb S, Marchiori A. Physical activity and PDE5 inhibitors in the treatment of erectile dysfunction: results of a randomized controlled study. The Journal of Sexual Medicine. 2010; 7: 2201–2208.
La Vignera S, Condorelli R, Vicari E, D’agata R, Calogero A. Aerobic physical activity improves endothelial function in the middle-aged patients with erectile dysfunction. The Aging Male. 2011; 14: 265–272.
Khoo J, Tian H, Tan B, Chew K, Ng C, Leong D, et al. Comparing Effects of Low- and High-Volume Moderate-Intensity Exercise on Sexual Function and Testosterone in Obese Men. The Journal of Sexual Medicine. 2013; 10: 1823–1832.
Maresca L, D’Agostino M, Castaldo L, Vitelli A, Mancini M, Torella G, et al. Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors. Monaldi Archives for Chest Disease. 2013; 80: 177–183.
Begot I, Peixoto TCA, Gonzaga LRA, Bolzan DW, Papa V, Carvalho ACC, et al. A Home-Based Walking Program Improves Erectile Dysfunction in Men with an Acute Myocardial Infarction. The American Journal of Cardiology. 2015; 115: 571–575.
Kirilmaz U, Guzel O, Aslan Y, Balci M, Tuncel A, Atan A. The effect of lifestyle modification and glycemic control on the efficiency of sildenafil citrate in patients with erectile dysfunction due to type-2 diabetes mellitus. The Aging Male. 2015; 18: 244–248.
Park M, Cho D, Yeo J, Cho S, Jung J, Yang S, et al. Exercise improves the effects of testosterone replacement therapy and the durability of response after cessation of treatment: a pilot randomized controlled trial. Asian Journal of Andrology. 2017; 19: 602–607.
Palm P, Zwisler AO, Svendsen JH, Thygesen LC, Giraldi A, Jensen KG, et al. Sexual rehabilitation for cardiac patients with erectile dysfunction: a randomised clinical trial. Heart. 2019; 105: 775–782.
Jones LW, Hornsby WE, Freedland SJ, Lane A, West MJ, Moul JW, et al. Effects of Nonlinear Aerobic Training on Erectile Dysfunction and Cardiovascular Function Following Radical Prostatectomy for Clinically Localized Prostate Cancer. European Urology. 2014; 65: 852–855.
Lamina S, Okoye CG, Dagogo TT. Therapeutic Effect of an Interval Exercise Training Program in the Management of Erectile Dysfunction in Hypertensive Patients. The Journal of Clinical Hypertension. 2009; 11: 125–129.
Salehi F, Mangolian Shahrbabaki P, Dehghan M, Amirihosseini M. Can passive pedaling improve sexual function in patients under hemodialysis? A randomized clinical trial. Therapeutic Apheresis and Dialysis. 2022; 26: 130–139.
Silva AB, Sousa N, Azevedo LF, Martins C. Physical activity and exercise for erectile dysfunction: systematic review and meta-analysis. British Journal of Sports Medicine. 2017; 51: 1419–1424.
Gerbild H, Larsen CM, Graugaard C, Areskoug Josefsson K. Physical Activity to Improve Erectile Function: a Systematic Review of Intervention Studies. Sexual Medicine. 2018; 6: 75–89.
Kodama S. Cardiorespiratory Fitness as a Quantitative Predictor of all-Cause Mortality and Cardiovascular Events in Healthy Men and Women: a meta-analysis. The Journal of American Medical Association. 2009; 301: 2024–2035.
Ezzatvar Y, Izquierdo M, Núñez J, Calatayud J, Ramírez-Vélez R, García-Hermoso A. Cardiorespiratory fitness measured with cardiopulmonary exercise testing and mortality in patients with cardiovascular disease: a systematic review and meta-analysis. Journal of Sport and Health Science. 2021; 10: 609–619.
Ekelund U, Tarp J, Steene-Johannessen J, Hansen BH, Jefferis B, Fagerland MW, et al. Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. British Medical Journal. 2019; 366; l4570.
Naci H, Ioannidis JPA. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. British Medical Journal. 2013; 347: f5577.
Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis. Journal of the American College of Cardiology. 2016; 67: 1–12.
Swardfager W, Herrmann N, Cornish S, Mazereeuw G, Marzolini S, Sham L, et al. Exercise intervention and inflammatory markers in coronary artery disease: a meta-analysis. American Heart Journal. 2012; 163: 666–676.e1–3.
Thompson G, Davison GW, Crawford J, Hughes CM. Exercise and inflammation in coronary artery disease: a systematic review and meta-analysis of randomised trials. Journal of Sports Sciences. 2020; 38: 814–826.
Rose GL, Skinner TL, Mielke GI, Schaumberg MA. The effect of exercise intensity on chronic inflammation: a systematic review and meta-analysis. Journal of Science and Medicine in Sport. 2021; 24: 345–351.
de Sousa CV, Sales MM, Rosa TS, Lewis JE, de Andrade RV, Simões HG. The Antioxidant Effect of Exercise: A Systematic Review and Meta-Analysis. Sports Medicine. 2017; 47: 277–293.
Sties SW, Andreato LV, de Carvalho T, Gonzáles AI, Angarten VG, Ulbrich AZ, et al. Influence of exercise on oxidative stress in patients with heart failure. Heart Failure Reviews. 2018; 23: 225–235.
Ashor AW, Lara J, Siervo M, Celis-Morales C, Oggioni C, Jakovljevic DG, et al. Exercise modalities and endothelial function: a systematic review and dose-response meta-analysis of randomized controlled trials. Sports Medicine. 2015; 45: 279–296.
Silva JKTNF, Menêses AL, Parmenter BJ, Ritti-Dias RM, Farah BQ. Effects of resistance training on endothelial function: a systematic review and meta-analysis. Atherosclerosis. 2021; 333: 91–99.
Zhang Y, Zhang YJ, Zhang HW, Ye WB, Korivi M. Low-to-Moderate-Intensity Resistance Exercise Is More Effective than High-Intensity at Improving Endothelial Function in Adults: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health. 2021; 18: 6723.
Qiu S, Cai X, Yin H, Sun Z, Zügel M, Steinacker JM, et al. Exercise training and endothelial function in patients with type 2 diabetes: a meta-analysis. Cardiovascular Diabetology. 2018; 17: 64.
Chen L, Staubli SEL, Schneider MP, Kessels AG, Ivic S, Bachmann LM, et al. Phosphodiesterase 5 Inhibitors for the Treatment of Erectile Dysfunction: a Trade-off Network Meta-analysis. European Urology. 2015; 68: 674–680.
Montero D, Roche E, Martinez-Rodriguez A. The impact of aerobic exercise training on arterial stiffness in pre- and hypertensive subjects: a systematic review and meta-analysis. International Journal of Cardiology. 2014; 173: 361–368.
Ashor AW, Lara J, Siervo M, Celis-Morales C, Mathers JC. Effects of exercise modalities on arterial stiffness and wave reflection: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 2014; 9: e110034.
Lopes S, Afreixo V, Teixeira M, Garcia C, Leitão C, Gouveia M, et al. Exercise training reduces arterial stiffness in adults with hypertension: a systematic review and meta-analysis. Journal of Hypertension. 2021; 39: 214–222.
Madeira CR, Tonin FS, Fachi MM, Borba HH, Ferreira VL, Leonart LP, et al. Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis. World Journal of Urology. 2021; 39: 953–962.
Mykoniatis I, Pyrgidis N, Sokolakis I, Ouranidis A, Sountoulides P, Haidich A, et al. Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis. JAMA Network Open. 2021; 4: e2036337.
Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction: a randomized clinical trial. Journal of the American Medical Association. 2013; 309: 1268–1277.
Kim K, Kim H, Hwang I, Cho H, Je N, Kwon O, et al. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; a 12-week, randomized, double-blind, placebo-controlled trial. American Heart Journal. 2015; 169: 813–822.e3.
Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, et al. Sildenafil Improves Exercise Capacity and Quality of Life in Patients with Systolic Heart Failure and Secondary Pulmonary Hypertension. Circulation. 2007; 116: 1555–1562.
De Vecchis R, Cesaro A, Ariano C. Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis. Minerva Cardioangiologica. 2018; 66: 659–670.
Hwang I, Kim Y, Park J, Yoon YE, Lee S, Kim H, et al. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials. BMC Cardiovascular Disorders. 2017; 17: 150.
Lederer DJ, Bartels MN, Schluger NW, Brogan F, Jellen P, Thomashow BM, et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD. 2012; 9: 268–275.
Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. The New England Journal of Medicine. 2010; 363: 620–628.
World Health Organization. Physical activity. 2020. Available at: (Accessed: 16 June 2022).
Allen MS. Physical activity as an adjunct treatment for erectile dysfunction. Nature reviews. Urology. 2019; 16: 553–562.
Back to top